GB2144991A - Hair growth promotor - Google Patents

Hair growth promotor Download PDF

Info

Publication number
GB2144991A
GB2144991A GB08419228A GB8419228A GB2144991A GB 2144991 A GB2144991 A GB 2144991A GB 08419228 A GB08419228 A GB 08419228A GB 8419228 A GB8419228 A GB 8419228A GB 2144991 A GB2144991 A GB 2144991A
Authority
GB
United Kingdom
Prior art keywords
hair
vitamin
adrenal
oestrogens
generating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08419228A
Other versions
GB8419228D0 (en
GB2144991B (en
Inventor
Yoshiaki Oshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB8419228D0 publication Critical patent/GB8419228D0/en
Publication of GB2144991A publication Critical patent/GB2144991A/en
Application granted granted Critical
Publication of GB2144991B publication Critical patent/GB2144991B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A topical hair growth preparation involving oestrogens, adrenal homones and vitamin B2 as main ingredients with low concentration and specified ratio of oestrogen to adrenal hormone.

Description

SPECIFICATION Agent for generating the hair BACKGROUND OF THE INVENTION Generally, there are many examples in which the ingredients of agents promoted for curing baldness or generating the hair are oestrogens and adrenal hormones. It has been widely believed that the reason why there are many bald-headed men but few or no bald-headed women is that men tend to have excessive androgens; however, no woman has such a tendency. It is thus clear why there are many examples in which oestrogens are proposed in agents to cure lack of hair, aiming to supplement natural oestrogens in cutaneous organization.
Agents containing oestrogens, with vitamin E or H, alcohol, menthol, etc., as their main ingredients, or those adding vitamin E or H, alcohol, menthol, etc. to adrenal hormones have been known. It is however a fact that these agents have no effect in generating the hair, without exception, yet recognising this fact, people use such ineffective agents with some expectation. Many examples have been found in which inflammations have occurred in the skin as well as failure to show hair growth, or even to cause loss of existing hair.
The inventor has made repeated researches in connection with the status of agents for generating the hair sold in the market as mentioned above, and the use of oestrogens and adrenal hormones certainly has a reasonability from the point of view of their characteristics. However, it was plain to the inventor that many matters remained to be researched for the conditions of use to be elucidated.
Adrenal hormones of a concentration of 0.5 per cent are for example used for circular epilation, but there is a problem of concentration for long term use. The inventor however has tested possibilities in a low concentration range that is not conventionally thought valuable. There is no example in-which oestrogens and adrenal hormones are used together, but the inventor has found the possibility of using them in a specific range of mixing ratios.
There have been some examples of using vitamins as promoting agent for metabolism of proteins, but it is important to search for a combination to demonstrate a precise and strong promoting action in the present context.
THE INVENTION The present invention has been completed as the result of investigations based on the ideas stated above, and provides an agent for generating the hair efficiently by applying it to the human head, without adverse side effects.
Thus there is provided a topical agent that comprises oestrogen 0.0033 to 1.0 mg%(i.e.
mg per 100 cc), adrenal hormone 0.018 to 2.75 mg%, and vitamin B2 from 0.085 up to 25.5 mg% as main ingredients thereof, conveniently dissolved in distilled water as a medium, with an oestrogen/adrenal hormone weight ratio of 0.01 to 4.0.
The following examples illustrate the invention, without limitation.
Example 1.
Embodiment 1 of this invention is as follows: an agent containing oestradiol benzoate (oestrogen) 0.005 mg; prednisolone acetate (adrenal hormone) 0.0275 mg; riboflavine phosphate (vitamin B2) 0.125 mg, and flavine-adenine dinucleotide (vitamin B2) 0.0025 mg asmain ingredients as well as chlorophenylamine maleate (antihistamine) 0.075 mg; pyridoxine hydrochloride (vitamin B6) 0.25 mg; nicotinamide 0.5 mg; pantothenyl alcohol 0.25 mg; and DL-methionine 1.0 mg were uniformly dissolved in refined water 100 cc.
To make this preparation material in liquid form in injection ampoules was used for each of the materials and the purity thereof was essentially 100 per cent. For example, oestra diol benzoate 0.2 mg was in aqueous suspension 1 cc in an ampoule; this liquid was uniformly dissolved in refined water, 4 litres and since this preparation is of a low concentration, the material is perfectly dissolved.
Specific amounts of the other materials contained respectively in 2 cc ampoules were also dissolved uniformly in the said refined water.
Example 2.
Next, as embodiment 2 of this invention, cortisone acetate (adrenal hormone) 0.0275 mg was used instead of the prednisolone acetate in embodiment 1, and the other materials and their quantities were as above.
In use, the agents are applied to the bald areas. Embodiments 1 and 2 give the maximum efficiency among many embodiments tried by the applicant and having effects for yielding the hair. Embodiments 1 and 2 differ only in the kinds of their adrenal hormones, the other conditions being the same; however, the effects for generating the hair of both are the same.
As the result of tests, changing various conditions, the applicant has shown that oestrogens, adrenal hormones and vitamin B2 play the roles of the main ingredients, in the relative amounts already given. It has been recognized that an effect for yielding the hair appears only when the three ingredients of oestrogens, adrenal hormones and vitamin B2 are respectively in the ranges given and also the quantitative ratio of the oestrogens to the adrenal hormones is as given.
Under such conditions, an effect in generating the hair appears; the maximum effect in yielding hair is seen at the quantitative relationship among the three main ingredients given in embodiments 1 and 2 above.
It is further noted that no inflammation in the skin occurs, because the oestrogens and the adrenal hormones have been made as ultra-low concentrations. Also the liquid does not reach such a quantity as to cause inflammation and to prevent hair generation if it is absorbed and accumulated into the skin.
Thus an agent for yielding hair according to this invention gives a good effect for generating hair but causes no inflammation of the skin. it has been known that vitamin B2 has an action in promoting metabolism of proteins, however, no example using vitamin B2 for yielding hair has been found before. In this invention it has been recognized that vitamin B2 gives a remarkable efficiency for generating the hair as a main ingredient, in the three-ingredient system of oestrogens, adrenal hormones and vitamin B2 Each ingredient other than the main ingredients added in the specific embodiments differs from the main ingredients and shows a specific effect.It is found that chlorophenylamine maleate intensifies the action of adrenal hormones and that pyridoxine hydrochloride, nicotinamide, pantothenyl alcohol, and DL-methionine have effects strengthening the action of vitamin B2 in the metabolism of proteins.
Examples of applying the agent are described below to show its efficiency.
Tests Applied: The tests were carried out by applying the liquid described in embodiment 1 above, once or twice a day with a rate of use of the liquid approximately from 50 to 100 cc a month.
The liquid was applied to 60 persons; hair generation and change in white hair to black were found for all of them. With the young bald-headed, efficiency was recognized in three months, and in addition, hair generation was also found even for a man as old as 75 years. Other examples are given below: (1) A man, 30 years old The liquid, 300 cc, was used for three months, once or twice a day; a bald patch on the left side of the head as large as the palm of a human hand was restored perfectly with the hair given.
(2) A man, 43 years old The liquid, 120 cc, was used for two months, once or twice a day; hair was completely- generated on a bald patch at the front of the head.
(3) A man, 30 years old The liquid, 1 20 cc, was for two months, once a day; a bald patch on the top of the head was restored with the hair generated.
(4) A man, 60 years old The liquid, 200 cc, was used for one and a half months, twice a day; his white and pale hair was changed to black with fresh growth.

Claims (2)

1. A topical agent for generating the hair, comprising oestrogen 0.0033 to 1.0 mg%.
adrenal hormone 0.018 to 2.75 mg% and vitamin B2 0.085 to 25.5 mg% the weight ratio of the oestrogen to the adrenal hormone being 0.01 to 4.0. in water or other medium.
2. An agent for generating the hair substantially as herein described in Example 1 or 2.
GB08419228A 1983-08-11 1984-07-27 Hair growth promotor Expired GB2144991B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58145708A JPS6038313A (en) 1983-08-11 1983-08-11 Hair restorer

Publications (3)

Publication Number Publication Date
GB8419228D0 GB8419228D0 (en) 1984-08-30
GB2144991A true GB2144991A (en) 1985-03-20
GB2144991B GB2144991B (en) 1987-04-15

Family

ID=15391281

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08419228A Expired GB2144991B (en) 1983-08-11 1984-07-27 Hair growth promotor

Country Status (6)

Country Link
JP (1) JPS6038313A (en)
KR (1) KR860001587B1 (en)
CA (1) CA1240618A (en)
DE (1) DE3417136C2 (en)
FR (1) FR2550448B1 (en)
GB (1) GB2144991B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012699A1 (en) * 1991-01-15 1992-08-06 Wolfgang Weuffen Cosmetic or pharmaceutical compositions for improving hair quality and promoting hair growth
WO2000018362A1 (en) * 1998-09-28 2000-04-06 Petersen, Sharleen, Caron Hair growth stimulant

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509354A1 (en) * 1994-12-08 1996-06-13 Klett Loch Lore M Combination preparation for promoting hair growth and possibly skin and nail growth and for preventing or eliminating hair loss
WO2024175703A1 (en) * 2023-02-24 2024-08-29 Giuliani S.P.A. Composition for improving the aesthetic appearance of hair and skin appendages

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2257223A1 (en) * 1972-11-22 1974-06-12 Fouad Dr Med Talabani Hair growth and anti- hairloss compsn. - contg. mixts of androgen, oestrogen, corticoid and carriers
JPS5879913A (en) * 1981-11-09 1983-05-13 Taizo Ayukawa Hair tonic composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012699A1 (en) * 1991-01-15 1992-08-06 Wolfgang Weuffen Cosmetic or pharmaceutical compositions for improving hair quality and promoting hair growth
US5629002A (en) * 1991-01-15 1997-05-13 Weuffen; Wolfgang Cosmetic or pharmaceutic preparations for improving hair quaility and stimulating growth of the hair
WO2000018362A1 (en) * 1998-09-28 2000-04-06 Petersen, Sharleen, Caron Hair growth stimulant

Also Published As

Publication number Publication date
KR860001587B1 (en) 1986-10-13
JPH0441123B2 (en) 1992-07-07
CA1240618A (en) 1988-08-16
JPS6038313A (en) 1985-02-27
FR2550448B1 (en) 1987-04-17
DE3417136A1 (en) 1985-02-21
DE3417136C2 (en) 1986-01-23
KR850002395A (en) 1985-05-13
GB8419228D0 (en) 1984-08-30
FR2550448A1 (en) 1985-02-15
GB2144991B (en) 1987-04-15

Similar Documents

Publication Publication Date Title
US4826683A (en) Decongestant
US5425954A (en) Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use
CA1187416A (en) Hair tonic composition
MXPA01011560A (en) Topical compositions for prostaglandin e1.
JPH02500976A (en) anti-inflammatory cream composition
US4927631A (en) Decongestant preparation
EP0216303B1 (en) External medication
GB2144991A (en) Hair growth promotor
FI962056A0 (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active ingredient comprising a combination of acetylsalicylic acid and metoclopramide
US5886038A (en) Composition and method for treatment of psoriasis
KR20020038595A (en) Topical Formulations Comprising Skin Penetration Agents and the Use Thereof
US3119739A (en) Acetylmethyl-salicylate for pain relief
EP0175701A1 (en) Skin treatment compositions
de Vlaming et al. Pituitary, adrenal and thyroid influences on osmoregulation in the euryhaline elasmobranch, Dasyatis sabina
Shafer et al. Salivary Gland Function in the Rat: III. Protease and Arginase Activity of Submaxillary Glands and Whole Saliva
GB2167957A (en) Hair growth stimulating compositions
JPS60237011A (en) Hair tonic composition
KR930010579B1 (en) Antifungus gel preparation
US4863950A (en) Medicinal formulation for promoting keratinogenesis and reducing seborrhea of the face and scalp
JPS6038315A (en) Hair tonic composition
JPS6361287B2 (en)
Schweizer et al. Effects of Adrenal and Thyroid Hormones on Water Exchange in Hypophysectomized Rats.
RU2025119C1 (en) Agent for hair washing
JPS59184116A (en) Hair grower
JPH1017457A (en) Percutaneous absorption-stimulating preparation for external use for skin

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee